EGR1 is a cancer suppressor and has been confirmed to be down-regulated in BC compared with normal tissues (Baron et al., 2006), but no studies revealed the regulatory relationship between it and CEMIP. EZH2 is classified as an oncogene, shows high expression in numerous cancers including breast cancer, and is discovered to contribute to global transcriptional repression, mainly targeting tumor suppressor genes (Eich et al., 2020). Here, EGR1 is linked to breast carcinoma.